Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Follow-Up Questions
Illumina Inc의 CEO는 누구입니까?
Mr. Jacob Thaysen은 2023부터 회사에 합류한 Illumina Inc의 Chief Executive Officer입니다.
ILMN 주식의 가격 성능은 어떻습니까?
ILMN의 현재 가격은 $117.01이며, 전 거래일에 increased 0.12% 하였습니다.
Illumina Inc의 주요 사업 주제나 업종은 무엇입니까?
Illumina Inc은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Illumina Inc의 시가총액은 얼마입니까?
Illumina Inc의 현재 시가총액은 $17.9B입니다
Illumina Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 23명의 분석가가 Illumina Inc에 대한 분석 평가를 실시했으며, 이는 8명의 강력한 매수, 6명의 매수, 13명의 보유, 2명의 매도, 그리고 8명의 강력한 매도를 포함합니다
